The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis
The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis
复制标题
DOI：
10.1093/rheumatology/keg326
复制
发表时间：
2003-05-01
期刊：
影响因子：
5.5
通讯作者：
Dayer, JM
中科院分区：
文献类型：
--
作者：
Dayer, JM
近年来，细胞因子网络在类风湿关节炎（RA）中介导炎症和关节破坏的作用已被广泛研究。白细胞介素-1（IL-1）和肿瘤坏死因子α（TNF α）是两种关键的促炎细胞因子，已被证明有助于RA的临床表现。IL-1驱动炎症和关节侵蚀以及抑制组织修复过程的能力已经在体外系统和动物模型中清楚地建立。在生理条件下，IL-1的活性被IL-1受体拮抗剂（IL-1 Ra）平衡。对IL-1和IL-1 Ra在健康和疾病状况中各自作用的理解导致了重组IL-1 ra，阿那白滞素的开发（Kineret（R）; Amgen Inc.，Thousand Oaks，CA），其为RA提供了新的治疗方式。
The role of the cytokine network in mediating inflammation and joint destruction in rheumatoid arthritis (RA) has been investigated extensively in recent years. Interleukin-1 (IL-1) and tumour necrosis factor alpha (TNFalpha) are two pivotal proinflammatory cytokines that have been shown to contribute to the clinical manifestations of RA. The ability of IL-1 to drive inflammation and joint erosion and to inhibit tissue repair processes has been clearly established in in vitro systems and animal models. Under physiological conditions, the activity of IL-1 is balanced by IL-1 receptor antagonist (IL-1Ra). Understanding of the respective roles of IL-1 and IL-1Ra in conditions of health and disease has led to the development of a recombinant IL-1ra, anakinra (Kineret(R); Amgen Inc., Thousand Oaks, CA), which offers a new therapeutic modality for RA.